Journal of Pharmaceutical Care & Health Systems
Open Access
ISSN: 2376-0419
ISSN: 2376-0419
Shuguang Hou
Sichuan Purity Pharmaceutical Technology Co., Ltd, China
Posters & Accepted Abstracts: J Pharma Care Health Sys
The inhalation drug delivery has entered a new era with two parallel pathways on generics and new indications respectively. Following the expiration of patents for inhaled drug blockbusters currently being used for asthma and chronic obstructive pulmonary diseases (COPD), development of generics has been a hot area for pharmaceutical industries. Considering the complexity of inhalation products, however, the regulatory agents are encountering a series of challenges on equivalence and bioequivalence requirements. Different approval pathways are observed between USA and Europe markets. The administration route via inhalation is also being explored for new clinical applications such as on the treatment of infections, cancers, diabetes and etc. These new indications lead to appearance of new pharmaceutical and device technologies. This article critically reviews the most recent advances from perspectives of regulation, technology and clinical applications to provide future directions to industrial and academic researchers.
Email: shuguang.hou@scpurity.com